These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27986691)

  • 1. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
    Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
    Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM; Mellors JW
    Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
    J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.
    Furukawa NW; Smith DK; Gonzalez CJ; Huang YA; Hanna DB; Felsen UR; Zhu W; Arnsten JH; Patel VV
    Public Health Rep; 2020; 135(2):202-210. PubMed ID: 32027559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
    Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
    MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
    Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
    Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 : A Retrospective Cohort Study.
    Furukawa NW; Zhu W; Huang YA; Shrestha RK; Hoover KW
    Ann Intern Med; 2020 Nov; 173(10):799-805. PubMed ID: 32894696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating statewide HIV preexposure prophylaxis implementation using All-Payer Claims Data.
    Raifman J; Nocka K; Galárraga O; Wilson IB; Crowley C; Tao J; Napoleon S; Marak T; Chan PA
    Ann Epidemiol; 2020 Apr; 44():1-7.e2. PubMed ID: 32279914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
    Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
    HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.
    Smith DK; Van Handel M; Wolitski RJ; Stryker JE; Hall HI; Prejean J; Koenig LJ; Valleroy LA
    MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1291-5. PubMed ID: 26606148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.
    Huang YA; Zhu W; Smith DK; Harris N; Hoover KW
    MMWR Morb Mortal Wkly Rep; 2018 Oct; 67(41):1147-1150. PubMed ID: 30335734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States.
    Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS
    Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.
    Coy KC; Hazen RJ; Kirkham HS; Delpino A; Siegler AJ
    J Int AIDS Soc; 2019 Feb; 22(2):e25252. PubMed ID: 30775846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.
    Chan SS; Chappel AR; Maddox KEJ; Hoover KW; Huang YA; Zhu W; Cohen SM; Klein PW; De Lew N
    PLoS Med; 2020 Apr; 17(4):e1003072. PubMed ID: 32275654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
    van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.